"
Team:MIT
From 2014.igem.org
(Difference between revisions)
| Line 15: | Line 15: | ||
</head> | </head> | ||
<body> | <body> | ||
| - | <table width= | + | |
| + | <table width=95% align=center> | ||
<tr> | <tr> | ||
<td width=33.3%>[Dying Neuron]<br>Neurodegenerative Disease</td> | <td width=33.3%>[Dying Neuron]<br>Neurodegenerative Disease</td> | ||
| Line 22: | Line 23: | ||
<tr> | <tr> | ||
</table> | </table> | ||
| - | |||
| - | |||
| - | |||
<table width=95% align=center> | <table width=95% align=center> | ||
| + | <tr><td><p align=left>Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by memory loss, behavioral problems… There is currently no cure for this disease, and existing diagnosis methods leave much to be desired. MIT iGEM 2014 has set out to change this. By detecting molecular biomarkers for AD, such as miRNAs and neurotoxic beta-amyloid plaques, and by regulating the production of beta-amyloid plaques, MIT iGEM hopes to create a dynamic solution for patients with Alzheimer’s disease. Looking ahead, … delivery.<br> | ||
| + | DETECT → TREAT → DELIVER</p></tr></td> | ||
| + | </table> | ||
| - | <tr><td colspan=3><h3>DETECTION</h3></td> | + | <table width=95% align=center> |
| + | <tr><td colspan=3><h3 style="font-size:25px">DETECTION</h3></td> | ||
</tr> | </tr> | ||
<tr> | <tr> | ||
| Line 36: | Line 38: | ||
<tr> | <tr> | ||
</table> | </table> | ||
| - | < | + | <br> |
| - | + | ||
<table width=75% align=center> | <table width=75% align=center> | ||
| - | <tr><td><h3>TREATMENT</h3></td> | + | <tr><td><h3 style="font-size:25px">TREATMENT</h3></td> |
| - | <td><h3>DELIVERY</h3></td> | + | <td><h3 style="font-size:25px">DELIVERY</h3></td> |
</tr> | </tr> | ||
<tr> | <tr> | ||
Revision as of 06:15, 15 October 2014
| Home |  Our Project
|
Lab Work
|
Outreach
|
About Us
|
Medals |
| [Dying Neuron] Neurodegenerative Disease |
[6th] Leading cause of death in the US |
[Vaccine] Current diagnosis and therapeutics are not effective |
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by memory loss, behavioral problems… There is currently no cure for this disease, and existing diagnosis methods leave much to be desired. MIT iGEM 2014 has set out to change this. By detecting molecular biomarkers for AD, such as miRNAs and neurotoxic beta-amyloid plaques, and by regulating the production of beta-amyloid plaques, MIT iGEM hopes to create a dynamic solution for patients with Alzheimer’s disease. Looking ahead, … delivery. |
DETECTION |
||
 Natural AB receptor |
 Engineered AB receptor |
 Sensors for Alzheimer’s state |
TREATMENT |
DELIVERY |
 |
 |
| Regulate AB production and degradation |
Ways to deliver our circuit |
